Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed. TAIPEI and SHANGHAI and SAN FRANCISCO, July 8, 2026 /PRNewswire/ — HanchorBio, Inc. (TWSE: 7827) is taking another step to…
Source: prnewswire
Country: United States